Shire Plc (SHP)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Shire Plc (SHP) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011964
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:88
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Shire Plc (Shire) is a biotechnology company that focuses on the research, development, manufacturing, marketing, distribution and sale of novel pharmaceuticals to serve patients with rare diseases and other highly specialized conditions. It provides products across various therapeutic areas including hematology, neuroscience, immunology, genetic disease, ophthalmic, gastrointestinal, endocrine, hereditary angioedema, cancer and other diseases. The company primarily sells its products through pharmaceutical wholesale distributors and large pharmacies, in both the US and Europe. The company operates along with its subsidiaries and representative offices in Europe, the Americas, Asia Pacific, South Africa and other countries. Shire is headquartered in Dublin, Ireland.

Shire Plc (SHP) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Shire Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Shire Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Shire Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Shire Plc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Shire Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Shire Plc, Medical Equipment, Deal Details 12
Venture Financing 12
Lotus Tissue Repair Secures US$26 Million In Series A Financing 12
DBV Technologies Secures US$25.5 Million In Series C Venture Financing Round 13
Partnerships 15
EM Imaging Enters into Licensing Agreement with GE Healthcare and Dyax 15
Zacharon Enters Into Licensing Agreement With Shire For Sensi Pro Assay 16
Shire Enters into Partnership with MicroHealth 17
Equity Offering 18
Dyax Completes Public Offering Of Shares For US$85 Million 18
Dyax Completes Public Offering Of Shares For US$69 Million 19
Dyax Completes Private Placement Of Shares For US$20.5 Million 21
Dyax Completes Private Placement Of Preferred Stock For US$9.5 Million 23
Debt Offering 25
Shire Raises USD3.3 Billion in Public Offering of 1.9% Notes Due 2019 25
Shire Raises USD2.5 Billion in Public Offering of 2.875% Notes Due 2023 27
Shire Raises USD3.3 Billion in Public Offering of 2.4% Notes Due 2021 29
Shire Raises USD3 Billion in Public Offering of 3.2% Notes Due 2026 31
Acquisition 33
Shire May Acquire Radius Health 33
Shire Acquires NPS Pharma for USD5.2 Billion 34
Shire Acquires Lotus Tissue Repair, Developer of Protein Replacement Therapy 36
Shire Completes Acquisition Of Advanced BioHealing 37
Shire Plc – Key Competitors 39
Shire Plc – Key Employees 40
Shire Plc – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Joint Venture 48
Recent Developments 49
Strategy And Business Planning 49
Apr 27, 2017: Shire opens new HQ office in Dublin City Centre 49
Dec 06, 2016: Planning permission granted for new Shire manufacturing site in Ireland 50
Nov 22, 2016: Shire to Establish Rare Disease Innovation Hub in Cambridge, Mass. 51
Financial Announcements 52
Oct 27, 2017: Shire Reports Strong Earnings Growth in Q3 2017; Reiterates Full Year Guidance 52
Aug 03, 2017: Shire reports strong Q2 2017 operating results and cash flow; updates full year guidance 56
May 02, 2017: Shire delivers strong Q1 2017 revenue growth while advancing late-stage pipeline 60
Feb 16, 2017: Shire Announces Full Year 2016 Results 65
Nov 01, 2016: Shire Reports Q3 2016 Results with Record Revenues and Reiterates Full Year Non GAAP Guidance 68
Aug 02, 2016: Shire Delivers Strong Q2 2016 Revenue Growth; Upgrades Outlook 71
Corporate Communications 75
Dec 08, 2017: Chief Financial Officer update 75
Dec 08, 2017: Shire: Chief Financial Officer update 76
Dec 01, 2017: Shire Appoints Andreas Busch, Ph D as Head of Research and Development and Chief Scientific Officer 77
Nov 20, 2017: Shire to Appoint Thomas Dittrich as Chief Financial Officer and Member of the Board of Directors 78
Aug 21, 2017: Shire Director and Senior Management Changes 79
Jan 13, 2017: Shire Joins Illinois Biotechnology Innovation Organization as Leadership Sponsor and Adds Shannon Resetich to the Board 80
Jan 03, 2017: Shire Appoints Ian Clark as Non-Executive Director 81
Jun 07, 2016: Shire Announces Directorate change 82
Legal and Regulatory 83
Feb 07, 2017: Shire Responds to US Federal Trade Commission Civil Action 83
Jun 14, 2016: Shire Announces Additional Listing 84
Other Significant Developments 85
Oct 24, 2017: Shire Launches OnePath Patient Portal and Mobile Application 85
Aug 25, 2017: Shire Announces Collaboration with MicroHealth to Address Unique Needs of Hemophilia A and B Patients with Inhibitors 86
Jun 03, 2016: Shire Completes Combination with Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized Conditions 87
Appendix 88
Methodology 88
About GlobalData 88
Contact Us 88
Disclaimer 88

List of Tables
Shire Plc, Medical Equipment, Key Facts, 2016 2
Shire Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Shire Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Shire Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Shire Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Shire Plc, Deals By Market, 2011 to YTD 2017 9
Shire Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Lotus Tissue Repair Secures US$26 Million In Series A Financing 12
DBV Technologies Secures US$25.5 Million In Series C Venture Financing Round 13
EM Imaging Enters into Licensing Agreement with GE Healthcare and Dyax 15
Zacharon Enters Into Licensing Agreement With Shire For Sensi Pro Assay 16
Shire Enters into Partnership with MicroHealth 17
Dyax Completes Public Offering Of Shares For US$85 Million 18
Dyax Completes Public Offering Of Shares For US$69 Million 19
Dyax Completes Private Placement Of Shares For US$20.5 Million 21
Dyax Completes Private Placement Of Preferred Stock For US$9.5 Million 23
Shire Raises USD3.3 Billion in Public Offering of 1.9% Notes Due 2019 25
Shire Raises USD2.5 Billion in Public Offering of 2.875% Notes Due 2023 27
Shire Raises USD3.3 Billion in Public Offering of 2.4% Notes Due 2021 29
Shire Raises USD3 Billion in Public Offering of 3.2% Notes Due 2026 31
Shire May Acquire Radius Health 33
Shire Acquires NPS Pharma for USD5.2 Billion 34
Shire Acquires Lotus Tissue Repair, Developer of Protein Replacement Therapy 36
Shire Completes Acquisition Of Advanced BioHealing 37
Shire Plc, Key Competitors 39
Shire Plc, Key Employees 40
Shire Plc, Other Locations 41
Shire Plc, Subsidiaries 41
Shire Plc, Joint Venture 48

★海外企業調査レポート[Shire Plc (SHP)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Genpact Limited:企業のM&A・事業提携・投資動向
    Genpact Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Genpact Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Airvolution Energy Limited:電力:M&Aディール及び事業提携情報
    Summary Airvolution Energy Limited (Airvolution) a subsidiary of Electricity Supply Board, is a renewable energy company that develops, construct and operate small onshore wind projects. It provides landowners a secure, long term revenue stream and takes all the financial risk during development of …
  • Siemens Heat Transfer Technology BV:企業の戦略的SWOT分析
    Siemens Heat Transfer Technology BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Infinity Pharmaceuticals Inc (INFI):製薬・医療:M&Aディール及び事業提携情報
    Summary Infinity Pharmaceuticals Inc (Infinity Pharmaceuticals) is a biopharmaceutical company that discovers and develops small molecule therapeutics for the treatment of cancer. The company’s pipeline candidate: IPI-549 selectively inhibits PI3K-gamma to reprogram tumor-associated macrophages and …
  • Western Gas Partners LP (WES):企業の財務・戦略的SWOT分析
    Summary Western Gas Partners LP (Western Gas), a subsidiary of Anadarko Petroleum Corp is an oil and gas company that acquires, owns, develops and operates midstream energy assets. The company's services include processing, compressing, gathering, treating and transporting natural gas, natural gas l …
  • Cell Therapy Catapult Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Cell Therapy Catapult Ltd (Catapult) is a provider of cell and gene therapy life cycle solutions. The company offers services such as industrialization, manufacturing, regulatory, health economics and market access, non-clinical safety and clinical operations. Its health economics and market …
  • Ciber, Inc.:企業の戦略・SWOT・財務情報
    Ciber, Inc. - Strategy, SWOT and Corporate Finance Report Summary Ciber, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Elong Inc:企業の戦略・SWOT・財務分析
    Elong Inc - Strategy, SWOT and Corporate Finance Report Summary Elong Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Autotelic Inc-製薬・医療分野:企業M&A・提携分析
    Summary Autotelic Inc (Autotelic) is a therapeutic drug monitoring company that develops novel treatments using its therapeutic drug monitoring (TDM) services. The company's pipeline products includes devices to improve safety and efficacy of COX-2 inhibitors, paclitaxel nanomedicine and TGF-beta in …
  • AbbVie Inc.:企業の戦略・SWOT・財務情報
    AbbVie Inc. - Strategy, SWOT and Corporate Finance Report Summary AbbVie Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Medical Facilities Corp (DR):製薬・医療:M&Aディール及び事業提携情報
    Summary Medical Facilities Corp (MFC) is a healthcare service provider that provides inpatient and outpatient surgical procedures. The hospital offers surgical equipment, non-surgical professional services, drugs and supplies, and other support services. Its specialty surgical division performs non- …
  • International Flavors & Fragrances Inc.:戦略・SWOT・企業財務分析
    International Flavors & Fragrances Inc. - Strategy, SWOT and Corporate Finance Report Summary International Flavors & Fragrances Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Star Gas Partners L.P.:企業の戦略・SWOT・財務情報
    Star Gas Partners L.P. - Strategy, SWOT and Corporate Finance Report Summary Star Gas Partners L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Vaccitech Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Vaccitech Ltd (Vaccitech) is a clinical stage company that focuses on the development of universal flu vaccines. The company is developing clinical programs for the treatment of influenza, prostate cancer, HBV, Middle East respiratory syndrome (MERS), shingles, human papillomavirus (HPV), an …
  • IRWIN Industrial Tool Co:企業の戦略的SWOT分析
    IRWIN Industrial Tool Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Gooch & Housego PLC:企業の戦略・SWOT・財務情報
    Gooch & Housego PLC - Strategy, SWOT and Corporate Finance Report Summary Gooch & Housego PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Statkraft AS:企業の戦略・SWOT・財務分析
    Statkraft AS - Strategy, SWOT and Corporate Finance Report Summary Statkraft AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Dignitana AB (DIGN):医療機器:M&Aディール及び事業提携情報
    Summary Dignitana AB (Dignitana), a subsidiary of Eurosund AB, designs, develops, manufactures and markets medical cooling systems.. The company’s DigniCap Scalp Cooling System helps reduce or eliminate hair loss in patients undergoing chemotherapy. The DigniCap system comprises a silicone cap and a …
  • Cellnet Group Ltd (CLT):企業の財務・戦略的SWOT分析
    Cellnet Group Ltd (CLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Hunter Oil Corp (HOC):企業の財務・戦略的SWOT分析
    Summary Hunter Oil Corp (HOC), formerly Enhanced Oil Resources Inc is an oil and gas company that offers energy production programs. The company offers production and rehabilitation of its legacy oil fields through full cycle development. It also provides full cycle development services such as rese …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆